{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:20:34Z","timestamp":1774977634578,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmcl.2026.130600","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:48:42Z","timestamp":1772005722000},"page":"130600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro investigations of troxacitabine (TROX) and 3\u2032-deazaneplanocin (DZNep) combination for pancreatic cancer therapy"],"prefix":"10.1016","volume":"136","author":[{"given":"Joseph","family":"Manu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth O.","family":"Agboluaje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew K.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May P.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2026.130600_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"10.1016\/j.bmcl.2026.130600_bb0010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130600_bb0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","article-title":"Metastatic patterns of cancers","volume":"132","author":"DiSibio","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130600_bb0020","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Howard","year":"1997","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130600_bb0025","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bmcl.2026.130600_bb0030","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130600_bb0035","first-page":"3747","article-title":"Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD\u2122 lenalidomide","volume":"31","author":"Fryer","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bmcl.2026.130600_bb0040","doi-asserted-by":"crossref","unstructured":"Nitipir C, Vrabie R, Parosanu AI, Tulin R, Cretu B. Clinical impact of the administration of FOLFIRINOX beyond six months in advanced pancreatic adenocarcinoma: A cohort study. 2021;13(11). doi:https:\/\/doi.org\/10.7759\/cureus.19361.","DOI":"10.7759\/cureus.19361"},{"issue":"19","key":"10.1016\/j.bmcl.2026.130600_bb0045","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130600_bb0050","series-title":"Anticancer Potential and Structure Activity Studies of Purine and Pyrimidine Derivatives: An Updated Review","author":"Manna","year":"2024"},{"key":"10.1016\/j.bmcl.2026.130600_bb0055","doi-asserted-by":"crossref","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Symposium article cellular pharmacology of gemcitabine Gemcitabine Ten Years Clin Exp 19\u201321 Sept 2005 Monast di Treviso, Italy 2006;17(Supplement 5):v7-v12. doi:https:\/\/doi.org\/10.1093\/annonc\/mdj941.","DOI":"10.1093\/annonc\/mdj941"},{"key":"10.1016\/j.bmcl.2026.130600_bb0060","unstructured":"Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the Antitumor Activity of Gemcitabine. Published online 1990:4417\u20134422."},{"key":"10.1016\/j.bmcl.2026.130600_bb0065","doi-asserted-by":"crossref","unstructured":"Gourdeau H, Ouellet F. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Published online 2001:236\u2013240. doi:https:\/\/doi.org\/10.1007\/s002800000223, Cancer Chemother Pharmacol.","DOI":"10.1007\/s002800000223"},{"issue":"14","key":"10.1016\/j.bmcl.2026.130600_bb0070","first-page":"3008","article-title":"Anticancer activity of \u03b2-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural l configuration","volume":"55","author":"Grove","year":"1995","journal-title":"Cancer Res"},{"issue":"40","key":"10.1016\/j.bmcl.2026.130600_bb0075","doi-asserted-by":"crossref","first-page":"28405","DOI":"10.1074\/jbc.274.40.28405","article-title":"Intracellular localization of human cytidine deaminase. Identification of a functional nuclear localization signal","volume":"274","author":"Somasekaram","year":"1999","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130600_bb0080","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/cmdc.201100139","article-title":"Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening","volume":"6","author":"Costanzi","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130600_bb0085","series-title":"Human Leukemic and Solid Tumor Cell Lines","first-page":"7217","article-title":"Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue","author":"Gourdeau","year":"2001"},{"issue":"4 B","key":"10.1016\/j.bmcl.2026.130600_bb0090","first-page":"2205","article-title":"Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer","volume":"28","author":"Ohhashi","year":"2008","journal-title":"Anticancer Res"},{"issue":"May","key":"10.1016\/j.bmcl.2026.130600_bb0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.crstbi.2022.05.005","article-title":"Current research in structural biology insight into the nucleoside transport and inhibition of human ENT1","volume":"4","author":"Wu","year":"2022","journal-title":"Curr Res Struct Biol"},{"key":"10.1016\/j.bmcl.2026.130600_bb0100","doi-asserted-by":"crossref","unstructured":"Sukumaran S. Combinatory effect of gemcitabine and 5-fluorouracil investigated through chemoinformatics and molecular dynamics simulation against breast cancer. Published online 2024. doi:https:\/\/doi.org\/10.1002\/qua.27498, Int J Quantum Chem.","DOI":"10.1002\/qua.27498"},{"key":"10.1016\/j.bmcl.2026.130600_bb0105","doi-asserted-by":"crossref","unstructured":"Sabini E, Hazra S, Konrad M, Burley SK, Lavie A. Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase. 2007;35(1):186\u2013192. doi:https:\/\/doi.org\/10.1093\/nar\/gkl1038.","DOI":"10.1093\/nar\/gkl1038"},{"key":"10.1016\/j.bmcl.2026.130600_bb0110","doi-asserted-by":"crossref","unstructured":"Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Published online 2007:1050\u20131063. doi:https:\/\/doi.org\/10.1101\/gad.1524107.aimed.","DOI":"10.1101\/gad.1524107"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130600_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bju.12702","article-title":"Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma","author":"Liu","year":"2016","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130600_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19123707","article-title":"Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation","volume":"19","author":"Mochizuki","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130600_bb0125","doi-asserted-by":"crossref","unstructured":"Hayden A, Johnson PWM, Packham G, Crabb SJ. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Published online 2011:109\u2013119. doi:https:\/\/doi.org\/10.1007\/s10549-010-0982-0, Breast Cancer Res Treat.","DOI":"10.1007\/s10549-010-0982-0"},{"key":"10.1016\/j.bmcl.2026.130600_bb0130","doi-asserted-by":"crossref","unstructured":"Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Published online 2012. doi:https:\/\/doi.org\/10.1007\/s10555-012-9387-3, Cancer Metastasis Rev.","DOI":"10.1007\/s10555-012-9387-3"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130600_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14814\/phy2.15810","article-title":"Dznep, a histone modification inhibitor, inhibits HIF1\u03b1 binding to TIMP2 gene and suppresses TIMP2 expression under hypoxia","volume":"11","author":"Yamazaki","year":"2023","journal-title":"Physiol Rep"},{"issue":"7330","key":"10.1016\/j.bmcl.2026.130600_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130600_bb0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3349\/ymj.2009.50.4.455","article-title":"Epigenetic cross-talk between DNA methylation and histone modifications in human cancers","volume":"50","author":"Kondo","year":"2009","journal-title":"Yonsei Med J"},{"issue":"7046","key":"10.1016\/j.bmcl.2026.130600_bb0150","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130600_bb0155","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/j.bmcl.2026.130600_bb0160","series-title":"(DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas","first-page":"1","author":"Lhuissier","year":"2021"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130600_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0071196","article-title":"Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies","volume":"8","author":"Hung","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130600_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2026.130600_bb0175","unstructured":"Chu, David C., K, Cho, Jong, Hyun, KIM, Hyo-Joon. 2007. Cyclopentanol Nucleoside Compounds, Intermediates for their synthesis and methods of treating viral infections. WO Patent no 2007\/047793 A2."},{"key":"10.1016\/j.bmcl.2026.130600_bb0180","unstructured":"Chu, David, C.K (2008). L- ODDC PRODRUGS FOR CANCER. WO Patent no 2008\/030373 A2."},{"issue":"May","key":"10.1016\/j.bmcl.2026.130600_bb0185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3 . 0\u00a0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130600_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56818-6","article-title":"AI-driven discovery of synergistic drug combinations against pancreatic cancer","volume":"16","author":"Pourmousa","year":"2025","journal-title":"Nat Commun"},{"issue":"September 2019","key":"10.1016\/j.bmcl.2026.130600_bb0195","article-title":"Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells","volume":"128","author":"Rawat","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130600_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-023-01454-4","article-title":"Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference","volume":"15","author":"Chan","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130600_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0468-0","article-title":"Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: Implications for in vivo mode of action","volume":"14","author":"Bartscht","year":"2015","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130600_bb0210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsmedchemlett.1c00627","article-title":"In silico optimized stapled peptides targeting WASF3 in breast cancer","volume":"13","author":"Limaye","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130600_bb0215","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-12-0037","article-title":"Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells","volume":"11","author":"Avan","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2026.130600_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-7-121","article-title":"Synergistic activity of troxacitabine (Troxatyl\u2122) and gemcitabine in pancreatic cancer","volume":"7","author":"Damaraju","year":"2007","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130600_bb0225","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"Cell adhesion & migration an introduction to the wound healing assay using live cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adhes Migr"},{"key":"10.1016\/j.bmcl.2026.130600_bb0230","series-title":"The Chemotactic Effect of Mixtures of Antibody and Antigen on Polymorphonuclear Leucocytes","first-page":"453","author":"Boyden","year":"1962"},{"key":"10.1016\/j.bmcl.2026.130600_bb0235","series-title":"Cell Migration","volume":"Vol 3","author":"Ortega-Carrion","year":"2022"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130600_bb0240","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jama.2019.10232","article-title":"Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA \u2013 J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130600_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jcpt.12655","article-title":"Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis","volume":"43","author":"Han","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"suppl 3","key":"10.1016\/j.bmcl.2026.130600_bb0250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1245\/s10434-011-2054-z","article-title":"Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy","volume":"19","author":"Morinaga","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130600_bb0255","doi-asserted-by":"crossref","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","article-title":"The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview","volume":"16","author":"Qui\u00f1onero","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.bmcl.2026.130600_bb0260","doi-asserted-by":"crossref","unstructured":"Gourdeau H, Genne \u00c6P, Kadhim \u00c6S, Bouffard J\u00c6DY. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Published online 2002:490\u2013496. doi:https:\/\/doi.org\/10.1007\/s00280-002-0530-7, Cancer Chemother Pharmacol.","DOI":"10.1007\/s00280-002-0530-7"},{"issue":"40","key":"10.1016\/j.bmcl.2026.130600_bb0265","doi-asserted-by":"crossref","first-page":"31009","DOI":"10.1074\/jbc.M004082200","article-title":"A novel action of human apurinic\/apyrimidinic endonuclease","volume":"275","author":"Chou","year":"2000","journal-title":"J Biol Chem"},{"issue":"39","key":"10.1016\/j.bmcl.2026.130600_bb0270","doi-asserted-by":"crossref","first-page":"23055","DOI":"10.1074\/jbc.270.39.23055","article-title":"L- and D-enantiomers of 2\u2032,3\u2032-dideoxycytidine 5\u2032-triphosphate analogs as substrates for human DNA polymerases: Implications for the mechanism of toxicity","volume":"270","author":"Kukhanova","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130600_bb0275","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett2 W. Difluorodeoxycytidine on DNA Synthesis \u2032, 2\u2032 Action of 2 E-mail alerts Action of 2\u2019,2\u2019-Difluorodeoxycytidine on DNA Synthesis1. 1991;51(22):6110-6117. http:\/\/cancerres.aacrjournals.org\/content\/51\/22\/6110."},{"key":"10.1016\/j.bmcl.2026.130600_bb0280","doi-asserted-by":"crossref","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder systems biology SynergyFinder: a web application for analyzing drug combination dose \u2013 response matrix data. Published online 2017:1\u20134. doi:https:\/\/doi.org\/10.1093\/bioinformatics\/btx162.","DOI":"10.1093\/bioinformatics\/btx162"},{"key":"10.1016\/j.bmcl.2026.130600_bb0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/CMO.S26537","article-title":"Gemcitabine-induced pulmonary toxicity: A case report of pulmonary veno-occlusive disease","volume":"9","author":"Turco","year":"2015","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.bmcl.2026.130600_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1740936","article-title":"Cancer stem cell quiescence and plasticity as major challenges in cancer therapy","volume":"2016","author":"Chen","year":"2016","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.bmcl.2026.130600_bb0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/d41586-019-00710-z","article-title":"Molecular envoys aid cancer spread","volume":"567","author":"Maitra","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130600_bb0300","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130600_bb0305","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:32:10Z","timestamp":1774974730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"alternative-id":["S0960894X26000673"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130600","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro investigations of troxacitabine (TROX) and 3\u2032-deazaneplanocin (DZNep) combination for pancreatic cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130600"}}